Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance
- PMID: 31974902
- PMCID: PMC7174472
- DOI: 10.1007/s11606-019-05539-w
Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance
Abstract
Background: Lung cancer screening (LCS) requires complex processes to identify eligible patients, provide appropriate follow-up, and manage findings. It is unclear whether LCS in real-world clinical settings will realize the same benefits as the National Lung Screening Trial (NLST).
Objective: To evaluate the impact of process modifications on compliance with LCS guidelines during LCS program implementation, and to compare patient characteristics and outcomes with those in NLST.
Design: Retrospective cohort study.
Setting: Kaiser Permanente Colorado (KPCO), a non-profit integrated healthcare system.
Patients: A total of 3375 patients who underwent a baseline lung cancer screening low-dose computed tomography (S-LDCT) scan between May 2014 and June 2017.
Measurements: Among those receiving an S-LDCT, proportion who met guidelines-based LCS eligibility criteria before and after LCS process modifications, differences in patient characteristics and outcomes between KPCO LCS patients and the NLST cohort, and factors associated with a positive screen.
Results: After modifying LCS eligibility confirmation processes, patients receiving S-LDCT who met guidelines-based LCS eligibility criteria increased from 45.6 to 92.7% (P < 0.001). Prior to changes, patients were older (68 vs. 67 years; P = 0.001), less likely to be current smokers (51.3% vs. 52.5%; P < 0.001), and less likely to have a ≥ 30-pack-year smoking history (50.0% vs. 95.3%; P < 0.001). Compared with NLST participants, KPCO LCS patients were older (67 vs. 60 years; P < 0.001), more likely to currently smoke (52.3% vs. 48.1%; P < 0.001), and more likely to have pulmonary disease. Among those with a positive baseline S-LDCT, the lung cancer detection rate was higher at KPCO (9.4% vs. 3.8%; P < 0.001) and was positively associated with prior pulmonary disease.
Conclusion: Adherence to LCS guidelines requires eligibility confirmation procedures. Among those with a positive baseline S-LDCT, comorbidity burden and lung cancer detection rates were notably higher than in NLST, suggesting that the study of long-term outcomes in patients undergoing LCS in real-world clinical settings is warranted.
Keywords: National Lung Screening Trial; lung cancer screening implementation.
Conflict of interest statement
The authors declare that they do not have a conflict of interest.
Figures
Similar articles
-
Positive Screens Are More Likely in a National Lung Cancer Screening Registry Than the National Lung Screening Trial.J Am Coll Radiol. 2025 Jun;22(6):644-652. doi: 10.1016/j.jacr.2025.02.012. Epub 2025 Feb 27. J Am Coll Radiol. 2025. PMID: 40023436
-
Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT.Cancer Epidemiol Biomarkers Prev. 2021 Aug;30(8):1472-1479. doi: 10.1158/1055-9965.EPI-20-1847. Epub 2021 Jun 9. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 34108138
-
Real-World Lung Cancer CT Screening Performance, Smoking Behavior, and Adherence to Recommendations: Lung-RADS Category and Smoking Status Predict Adherence.AJR Am J Roentgenol. 2021 Apr;216(4):919-926. doi: 10.2214/AJR.20.23637. Epub 2021 Feb 17. AJR Am J Roentgenol. 2021. PMID: 32755178
-
Low Dose Computed Tomography for Lung Cancer Screening in Tuberculosis Endemic Countries: A Systematic Review and Meta-Analysis.J Thorac Oncol. 2025 Mar;20(3):296-310. doi: 10.1016/j.jtho.2024.11.020. Epub 2024 Nov 22. J Thorac Oncol. 2025. PMID: 39581379
-
The 10 Pillars of Lung Cancer Screening: Rationale and Logistics of a Lung Cancer Screening Program.Radiographics. 2015 Nov-Dec;35(7):1893-908. doi: 10.1148/rg.2015150079. Epub 2015 Oct 23. Radiographics. 2015. PMID: 26495797 Review.
Cited by
-
Lung Cancer Screening Knowledge and Perceived Barriers Among Physicians in the United States.JTO Clin Res Rep. 2022 Apr 22;3(7):100331. doi: 10.1016/j.jtocrr.2022.100331. eCollection 2022 Jul. JTO Clin Res Rep. 2022. PMID: 35769389 Free PMC article.
-
Lung Cancer Screening Participation Among Indigenous Peoples Worldwide: A Systematic Review of Challenges and Opportunities.Health Promot J Austr. 2025 Apr;36(2):e70001. doi: 10.1002/hpja.70001. Health Promot J Austr. 2025. PMID: 39994911 Free PMC article.
-
The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.J Med Screen. 2023 Mar;30(1):3-13. doi: 10.1177/09691413221117685. Epub 2022 Aug 9. J Med Screen. 2023. PMID: 35942779 Free PMC article.
-
Risk factors and prognostic nomogram for patients with second primary cancers after lung cancer using classical statistics and machine learning.Clin Exp Med. 2023 Sep;23(5):1609-1620. doi: 10.1007/s10238-022-00858-5. Epub 2022 Jul 11. Clin Exp Med. 2023. PMID: 35821159
-
Positive Screens Are More Likely in a National Lung Cancer Screening Registry Than the National Lung Screening Trial.J Am Coll Radiol. 2025 Jun;22(6):644-652. doi: 10.1016/j.jacr.2025.02.012. Epub 2025 Feb 27. J Am Coll Radiol. 2025. PMID: 40023436
References
-
- Caverly TJ, Fagerlin A, Wiener RS, Slatore CG, Tanner NT, Yun S, et al. Comparison of Observed Harms and Expected Mortality Benefit for Persons in the Veterans Health Affairs Lung Cancer Screening Demonstration Project. JAMA Intern Med. 2018;178(3):426–8. doi: 10.1001/jamainternmed.2017.8170. - DOI - PMC - PubMed
-
- Begnaud A, Hall T, Allen T. Lung Cancer Screening With Low-Dose CT: Implementation Amid Changing Public Policy at One Health Care System. Am Soc Clin Oncol Educ Book. 2016;35:e468–75. doi: 10.14694/edbk_159195. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous